Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib: A Selective Cyclo-Oxygenase-2 Inhibitor

By Davies N.M.  

Clinical Pharmacokinetics, Vol. 38, Iss. 3, 2000-03 ,pp. : 225-242

Adis International

Access to resources Recommend Favorite

The cyclo-oxygenase-2 inhibitor, rofecoxib, attenuates mucosal damage due to colitis induced by trinitrobenzene sulphonic acid in rats

By Martin A.R.   Villegas I.   La Casa C.   Alarcon de la Lastra C.  

European Journal of Pharmacology, Vol. 481, Iss. 2, 2003-11 ,pp. : 281-291

Elsevier

Access to resources Recommend Favorite

Clinical Pharmacology of Lumiracoxib: A Selective Cyclo-Oxygenase-2 Inhibitor

By Rordorf Christiane M.  

Clinical Pharmacokinetics, Vol. 44, Iss. 12, 2005-01 ,pp. : 1247-1266

Adis International

Access to resources Recommend Favorite

The injectable cyclo-oxygenase-2 inhibitor parecoxib shows comparable efficacy to ketorolac

By  

Inpharma, Vol. 1, Iss. 1264, 2000-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database

By Lugardon S.   Lapeyre-Mestre M.   Montastruc J.  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 9, 2004-11 ,pp. : 673-677

Springer Publishing Company

Access to resources Recommend Favorite